Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, after nearly three ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...

Despite challenges like high costs and regulatory complexities, Europe's vibrant research ecosystem and EMA's supportive ATMP ...

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

The trial was small — just 12 children were treated in one or both ears — but it offers important lessons for researchers about the potential of Regeneron’s gene therapy.

A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.

The search for gene therapies to treat rheumatoid arthritis (RA) has moved in fits and starts over the past two decades, with trials starting and stopping, and their focus shifting to osteoarthritis ...

A new gene therapy can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the amount of blood the heart can pump and dramatically improves ...